Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q3 2022 · 10-Q
Revenue$142.00K$142.00K+31.5% vs Q3 2021 Net Income-$2.38M-$2.38MN/M vs Q3 2021 EPS Diluted-$0.05-$0.05N/M vs Q3 2021 Gross Profit$62,000+342.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,422,000N/M Free Cash Flowderived-$2,449,000N/M Margins · derivedGross margin43.7%+30.7 pt vs Q3 2021
Operating margin-1679.6%+474.1 pt vs Q3 2021
Net margin-1676.8%+474.2 pt vs Q3 2021
ended Dec 31, 2021 · filed Feb 10, 2022 · 41 d after period end